TGA approves ‘game changing’ ovarian cancer drug bringing new hope to patients

18 January 2022 - Federal health authorities have approved a breakthrough drug for ovarian cancer, bringing a game-changing treatment option ...

Read more →

TGA recognises the Gamaleya Institute vaccine (Sputnik V, Russian Federation) for international travel to Australia

17 January 2022 - Today, the TGA determined that an additional COVID-19 vaccine, the two dose course of the Gamaleya ...

Read more →

ATAGI update following weekly COVID-19 meeting (12 January 2022)

17 January 2022 - Previously, severely immunocompromised people aged 12 years and older were recommended to receive a third primary dose ...

Read more →

COVID-19 vaccine weekly safety report (13 January 2022)

13 January 2022 - To 9 January 2022, the TGA has received 952 reports which have been assessed as likely to ...

Read more →

COVID-19 vaccine weekly safety report (6 January 2022)

17 January 2022 - To 2 January 2022, the TGA has received 415 reports which have been assessed as likely to ...

Read more →

TGA grants provisional determination to AstraZeneca for COVID-19 prophylaxis and treatment, tixagevimab and cilgavimab (Evusheld)

4 January 2022 - On 4 January 2022, the TGA granted a further provisional determination to AstraZeneca in relation to ...

Read more →

COVID-19 vaccine weekly safety report (23 December 2021)

23 December 2021 - To 19 December 2021, the TGA has received 415 reports which have been assessed as likely to ...

Read more →

ATAGI update following weekly COVID-19 meeting (15 December 2021)

18 December 2021 - On Wednesday 15 December 2021 ATAGI reviewed the latest developments relating to COVID-19 and COVID-19 vaccine safety.  ...

Read more →

COVID-19 vaccine weekly safety report (16 December 2021)

16 December 2021 - To 12 December 2021, the TGA has received approximately 290 reports of suspected adverse events identified as ...

Read more →

TGA approves new medicine for paediatric cancer

15 December 2021 - Another new cancer medicine from AstraZeneca. ...

Read more →

Access Consortium statement on COVID-19 medicines

14 December 2021 - Vaccines have played a critical role in fighting the COVID-19 pandemic. However, medicines can still play ...

Read more →

mRNA manufacturing facility will deliver long term health benefits for Australians

14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...

Read more →

Moderna vaccine deal to produce 100 million doses in Melbourne reached by Federal and Victorian Governments

13 December 2021 - Australia is poised to become the largest producer of mRNA vac­cines outside the US and Europe ...

Read more →

ACCC helps to protect Australians against medicine shortages caused by COVID-19

10 December 2021 - Medicine shortages from the COVID-19 pandemic will continue to be actively managed by Medicines Australia and ...

Read more →

Australian Technical Advisory Group on Immunisation recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine

12 December 2021 - Spikevax (Moderna), also referred to as the Moderna COVID-19 vaccine, has been provisionally approved for use as ...

Read more →